A first-in-human study of the fibroblast activation protein–targeted, 4-1BB agonist RO7122290 in patients with advanced solid tumors
Authors:
- Ignacio MeleroIMIgnacio Melero
- Tamara TanosTTTamara Tanos
- Mariana BustamanteMBMariana Bustamante
- Emiliano CalvoECEmiliano Calvo
- Irene MorenoIMIrene Moreno
- Victor MorenoVictor Moreno
- Tatiana HernandezTHTatiana Hernandez
- Maria Martinez GarciaMGMaria Martinez Garcia
- Alejo Rodriguez-VidaARAlejo Rodriguez-Vida
- Josep TaberneroJTJosep Tabernero
- Analia AzaroAAAnalia Azaro
- 10 May 2023
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 15 (695) , eabp9229
Abstract
This first-in-human study evaluated RO7122290, a bispecific fusion protein carrying a split trimeric 4-1BB (CD137) ligand and a fibroblast activation protein α (FAP) binding site that costimulates T cells for improved tumor cell killing in FAP-expressing tumors. Patients with advanced or metastatic solid tumors received escalating weekly intravenous doses of RO7122290 as a single agent ( n = 65) or in combination with a 1200-milligram fixed dose of the anti–programmed death-ligand 1 (anti–PD-L1) antibody atezolizumab given every 3 weeks ( n = 50), across a tested RO7122290 dose range of 5 to 2000 milligrams and 45 to 2000 milligrams, respectively. Three dose-limiting toxicities were reported, two at different RO7122290 single-agent doses (grade 3 febrile neutropenia and grade 3 cytokine release syndrome) and one for the combination (grade 3 pneumonitis). No maximum tolerated dose was identified. The pharmacokinetic profile of RO7122290 suggested nonlinearity in elimination. The observed changes in peripheral and tissue pharmacodynamic (PD) biomarkers were consistent with the postulated mechanism of action. Treatment-induced PD changes included an increase in proliferating and activated T cells in peripheral blood both in the single-agent and combination arms. Increased infiltration of intratumoral CD8 + and Ki67 + CD8 + T cells was observed for both treatment regimens, accompanied by the up-regulation of T cell activation genes and gene signatures. Eleven patients experienced a complete or partial response, six of whom were confirmed to be immune checkpoint inhibitor naive. These results support further evaluation of RO7122290 in combination with atezolizumab or other immune-oncology agents for the treatment of solid tumors.Keywords
This publication has 58 references indexed in Scilit:
- featureCounts: an efficient general purpose program for assigning sequence reads to genomic featuresBioinformatics, 2013
- STAR: ultrafast universal RNA-seq alignerBioinformatics, 2012
- Rationale Behind Targeting Fibroblast Activation Protein–Expressing Carcinoma-Associated Fibroblasts as a Novel Chemotherapeutic StrategyMolecular Cancer Therapeutics, 2012
- Difference Tracker: ImageJ plugins for fully automated analysis of multiple axonal transport parametersJournal of Neuroscience Methods, 2010
- Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In VivoMolecular Therapy, 2009
- Hypercostimulation through 4-1BB Distorts Homeostasis of Immune CellsThe Journal of Immunology, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Simultaneous Inference in General Parametric ModelsBiometrical Journal, 2008
- Functional CD137 receptors are expressed by eosinophils from patients with IgE-mediated allergic responses but not by eosinophils from patients with non–IgE-mediated eosinophilic disordersJournal of Allergy and Clinical Immunology, 2001
- Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumorsNature Medicine, 1997